Fever News and Research

RSS

Mayo Clinic expert explains difference between severe sepsis and septic shock

Sepsis can be a dangerous complication of almost any type of infection, including influenza, pneumonia and food poisoning; urinary tract infections; bloodstream infections from wounds; and abdominal infections.

14 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Study confirms safety of two measles-containing vaccines

A 12-year study of two measles-containing vaccines, published today in Pediatrics, found that seven main adverse outcomes were unlikely after either vaccine.

5 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

31 Dec 2014

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Infectious disease specialist underscores the importance of flu vaccines

Flu season is in full swing, but it's not too late to get a flu vaccine. In fact, it's never been easier and more convenient.

23 Dec 2014

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.

19 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Two studies shed new light on risks associated with blood transfusions

Two studies published in the January issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, shed new light on the prevalence of transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), the number one and two leading causes of blood transfusion-related deaths in the United States.

16 Dec 2014

Study: New flooring can increase risk of respiratory diseases in infants

New flooring in the living environment of pregnant women significantly increases the risk of infants to suffer from respiratory diseases in their first year of life. This is the result of a study carried out by the Helmholtz Centre for Environmental Research and the "St Georg" Municipal Hospital, which demonstrates that exposure to volatile organic compounds in the months before and after birth induces breathing problems in early childhood .

16 Dec 2014

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings.

16 Dec 2014

Potential new active substances for treating dengue virus

Researchers from Johannes Gutenberg University Mainz and the Julius Maximilian University of Würzburg are proposing potential new active substances for treating the dengue virus. Just like Ebola, dengue fever is also caused by a virus for which there is currently no cure and no vaccine and can be fatal.

11 Dec 2014

Malaria deaths decline by 54% in Africa, 47% worldwide

The number of people dying from malaria has fallen dramatically since 2000 and malaria cases are also steadily declining, according to the World Malaria Report 2014. Between 2000 and 2013, the malaria mortality rate decreased by 47% worldwide and by 54% in the WHO African Region - where about 90% of malaria deaths occur.

9 Dec 2014

Infant mortality rates for RSV much lower than previously thought

It's a virus that has long been characterized as dangerous and even deadly, but new research shows infant deaths from respiratory syncytial virus (RSV) are actually quite uncommon in the 21st century.

9 Dec 2014

Good first aid kit can help make your vacation perfect

Planning a vacation? Make a little room in your luggage for a travel first aid kit. It won't cost much, and it won't take up much space. Once you reach your destination, you won't need to reach any further than your suitcase to relieve those minor aches and pains that can put a major damper on your plans.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight (Antihemophilic Factor [Recombinant]) showed the largest reduction in bleeding over the duration of treatment.

From Novo Nordisk 7 Dec 2014

New diagnostic system describes symptoms using the image of patient's tongue

Physicians often ask their patients to "Please stick out your tongue". The tongue can betray signs of illness, which combined with other symptoms such as a cough, fever, presence of jaundice, headache or bowel habits, can help the physician offer a diagnosis. For people in remote areas who do not have ready access to a physician, a new diagnostic system is reported in the International Journal of Biomedical Engineering and Technology that works to combine the soft inputs of described symptoms with a digital analysis of an image of the patient's tongue.

7 Dec 2014

Fever News and Research

Mayo Clinic expert explains difference between severe sepsis and septic shock

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

Study confirms safety of two measles-containing vaccines

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

OncoGenex executes initial agreement with Teva to regain rights to custirsen

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Infectious disease specialist underscores the importance of flu vaccines

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Two studies shed new light on risks associated with blood transfusions

Study: New flooring can increase risk of respiratory diseases in infants

Roche announces launch of cobas Liat System for on-demand testing in different settings

Potential new active substances for treating dengue virus

Malaria deaths decline by 54% in Africa, 47% worldwide

Infant mortality rates for RSV much lower than previously thought

Good first aid kit can help make your vacation perfect

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Novel targeted therapies and treatment combinations for leukemia

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

New diagnostic system describes symptoms using the image of patient's tongue

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News